Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates

Docrates, a private cancer center based in Helsinki, Finland, is the only private cancer hospital in the Nordics. It offers personalized care throughout the entire patient journey, supported by leading experts in the field to ensure the highest quality of care. As part of the Mehiläinen Group, a well-known and respected private provider of social and healthcare services, Docrates is dedicated to adopting cutting-edge innovations to meet its patients’ needs and enhance their care.

Simsen Diagnostics’ solution, Simsen® Personal, is a highly sensitive, patient-specific test that detects circulating tumor DNA (ctDNA), a biomarker directly associated with the patient’s tumor. It tracks unique mutations to provide a detailed view of tumor dynamics. Using simple blood samples, the test monitors ctDNA levels over time, offering a minimally invasive way to detect even the smallest traces of cancer – potentially years before traditional methods.

Docrates recognizes the potential of this technology and the advantages of personalized tests in enhancing patient care. The goal is to utilize these assays for early detection of recurring cancer and residual disease, and for monitoring treatment effectiveness, including early indicators of response or resistance. A key aspect of this collaboration is achieving faster results compared to previous efforts. By integrating Simsen® Personal into Docrates’ practice, the solution can enable more personalized and optimized patient care, ultimately improving outcomes and increasing the chances of saving lives.

“We are pleased to integrate Simsen’s ctDNA analysis into our practice. This innovative technology aligns perfectly with Docrates’ commitment to providing personalized, cutting-edge cancer care. By leveraging the power of Simsen® Personal, we enhance our ability to monitor treatment responses and detect recurrences early, which will hopefully increase available treatment options and ultimately improve outcomes for our patients. This collaboration represents a significant advancement in our mission to deliver tailored care throughout the cancer journey.”

— Dr. Juha Kononen, Chief Clinical Director, Docrates Cancer Center

“The essence of Simsen Diagnostics is our commitment to a personalized approach in everything we do, from personalized assays to personalized customer service, which is very much in line with Docrates’ approach to providing personalized care. Our collaboration brings Simsen® Personal one step closer to patients, and we couldn’t be more excited about the opportunity to potentially improve their lives.”,

— Pontus Rehn, CEO, Simsen Diagnostics.

About Docrates

At Docrates Cancer Center, patients with cancer receive personalized care under one roof throughout their treatment and follow-up period. The hospital’s operations emphasize personalized and timely cancer treatments, alongside a commitment to quality, training, and research. Docrates operates a hospital in Helsinki, Finland, with a team of over 130 cancer care professionals. As a leading private cancer hospital, Docrates is a pioneer in Europe and the only one of its kind in the Nordic countries. https://www.docrates.com/en/  

Docrates is part of Mehiläinen Group, a well-known and highly valued private provider of social and health care services, offering comprehensive high-quality services in Finland and internationally. Mehiläinen serves 2.1 million customers annually, and services are produced at 840 locations by more than 37,000 employees and private practitioners. Internationally, Mehiläinen provides healthcare services in Sweden, Germany, and Estonia, as well as digital healthcare software solutions through its subsidiary BeeHealthy. https://www.mehilainen.fi/en

About Simsen Daignostics

Simsen Diagnostics is a biotech startup focusing on transforming cancer monitoring. Specialized in designing patient-specific tests, Simsen® Personal, the flagship solution, is based on ultrasensitive sequencing technology capable of detecting cancer years before standard-of-care tools. Founded in 2020, as a research spin-out from Sahlgrenska Academy, Simsen Diagnostics has experienced steady growth, gaining recognition from e.g. the pharmaceutical industry. Situated in the BioVentureHub at AstraZeneca Gothenburg, the company is at the forefront of providing innovative solutions in cancer management and monitoring. https://simsendiagnostics.com/